This episode features Sandra Visser and Anne Chain from Merck & Co/MSD, discussing existing practice and modeling approaches and some thoughts with regard to future directions for modeling to assess and predict cardiovascular liabilities of new drugs. You can read Dr. Visser’s Review “Implementation of Quantitative and Systems Pharmacology in Large Pharma” by clicking here.
This episode features Lutz Harnisch from Clinical Pharmacology Pharmacometrics at Pfizer, discussing the Drug Disease Model Resources (DDMoRe) consortium. His Perspective article that introduces the activities of the DDMoRe consortium can also be found here.
In this episode, we interview Dr. Shiew-Mei Huang, Deputy Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research at the Food and Drug Administration about a drug interaction database–a tool for evaluating the impact of renal or hepatic impairment in a pharmacologic inhibition on the systemic exposure of drugs. Read the article here. An Editorial describing the new Database article type can also be found here.
In this episode, we interview Dr. Steven E. Kern, Deputy Director of Quantitative Sciences at the Bill and Melinda Gates Foundation, about infectious diseases in context of the possibilities for pharmacometrics and systems pharmacology to contribute to improve treatments in the area. You can view PSP’s Infectious Diseases virtual issue online to view the most recently published articles related to this field by clicking here.